PBH · XBRL financial data

Prestige Consumer Healthcare financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PBH's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue from contracts with customers	943	1,087	1,128	1,125	1,138	1,089
Cost of revenue	396	466	502	501	503	493
Gross profit	547	621	625	624	634	596
General and administrative	86	109	107	106	108	116
Total operating expenses	250	291	648	282	298	286
Operating income (loss)	297	330	(22)	342	337	309
Interest expense	82	64	4	5	2	—
Other income (expense)	1	(1)	(2)	1	(5)	(10)
Income tax expense (benefit)	39	57	(12)	67	70	67
Net income (loss)	165	205	(82)	209	215	190
Earnings per share, basic USD per share	3.28	4.09	(1.65)	4.21	4.32	3.93
Earnings per share, diluted USD per share	3.25	4.04	(1.65)	4.17	4.29	3.91
Weighted average shares, basic millions of shares	50	50	50	50	50	48
Weighted average shares, diluted millions of shares	51	51	50	50	50	49

Fiscal years (PBH's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	32	27	58	46	98	64
Accounts receivable	115	139	167	177	194	192
Inventory	115	120	162	139	148	159
Prepaid and other current assets	8	6	4	13	8	17
Total current assets	270	293	392	375	448	431
Property and equipment, net	70	71	70	77	75	122
Right-of-use asset	24	20	15	11	28	28
Goodwill	578	579	528	528	527	581
Total assets	3,429	3,671	3,354	3,318	3,402	3,494
Accounts payable	46	56	63	39	19	23
Current portion of long-term debt	0	—	—	—	—	0
Total current liabilities	122	143	161	117	107	121
Long-term debt	1,480	1,477	1,346	1,126	—	994
Lease liability, non-current	20	16	10	8	23	21
Total liabilities	2,071	2,093	1,907	1,663	1,567	1,607
Retained earnings	1,009	1,214	1,132	1,341	1,556	1,746
Total stockholders' equity	1,358	1,578	1,447	1,655	1,835	1,888
Total liabilities and equity	3,429	3,671	3,354	3,318	3,402	3,494
Common shares outstanding (cover page) millions of shares	50	50	50	50	49	47

Fiscal years (PBH's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	165	205	(82)	209	215	190
Stock-based compensation	—	—	12	14	11	11
Depreciation and amortization	30	32	33	31	30	31
Net cash from operating activities	236	260	230	249	252	258
Purchases of property and equipment	22	10	8	10	8	11
Net cash from investing activities	(22)	(257)	(12)	(20)	(17)	(137)
Share repurchases	12	0	50	25	52	156
Net cash from financing activities	(279)	(8)	(186)	(241)	(182)	(156)
Net change in cash	(62)	(5)	31	(12)	51	(34)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026
Viking Therapeutics	678	0	(138)*	127.5M	7.6 quarters	Q3 FY26 10-QSep 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.